Toric extended depth-of-focus IOLs appear to offer reliable
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The authors evaluated the outcomes of bilateral toric extended depth-of-focus intraocular lens (EDOF IOL) implantation targeted for micromonovision.

This was a single-site, prospective case series study that included 52 eyes of 26 patients with regular corneal astigmatism from 0.75 to 2.60 D that were implanted bilaterally with a toric EDOF IOL targeted for micromonovision. The authors assessed postoperative visual acuity, astigmatism reduction, rotation, tilt, decentration, spectacle independence, patient satisfaction, and photic phenomena.

This study highlighted the use of diffractive optics. The dominant eye was targeted for emmetropia. The non-dominant eye was targeted a minimal residual myopia of -0.5 D. Study patients achieved superior UDVA and UIVA with improved UNVA due to the micromonovision. The use of toric EDOF IOL implantation targeted for micromonovision resulted in reliable reduction of preoperative astigmatism with a high degree of postoperative rotational predictability and centration, enabling functional distance, intermediate and near vision, which manifested itself in high patient satisfaction.

Toric lenses continued to be adopted at an alarmingly low rate. But why? Available data suggest the lenses perform incredibly well throughout ranges of vision with many different technologies. Even in premium EDOF technologies, this study highlights how beneficial a toric lens is in reducing a patient’s astigmatism. It would appear that if there is a change in the reimbursement of toric IOLs in the United States, these lenses would be adopted at a much higher rate.